• Something wrong with this record ?

Overexpression of MRP1/ABCC1, Survivin and BCRP/ABCC2 Predicts the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Treatment

D. Mandić, L. Nežić, L. Amdžić, N. Vojinović, R. Gajanin, M. Popović, J. Đeri, MT. Balint, J. Dumanović, Z. Milovanović, J. Grujić-Milanović, R. Škrbić, V. Jaćević

. 2023 ; 15 (16) : . [pub] 20230815

Status not-indexed Language English Country Switzerland

Document type Journal Article

BACKGROUND: Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience treatment resistance to the first-line R-CHOP regimen. ATP binding cassette (ABC) transporters and survivin might play a role in multidrug resistance (MDR) in various tumors. The aim was to investigate if the coexpression of ABC transporters and survivin was associated with R-CHOP treatment response. METHODS: The expression of Bcl-2, survivin, P-glycoprotein/ABCB1, MRP1/ABCC1, and BCRP/ABCC2 was analyzed using immunohistochemistry in tumor specimens obtained from patients with DLBCL, and classified according to the treatment response as Remission, Relapsed, and (primary) Refractory groups. All patients received R-CHOP or equivalent treatment. RESULTS: Bcl-2 was in strong positive correlation with clinical parameters and all biomarkers except P-gp/ABCB1. The overexpression of MRP1/ABCC1, survivin, and BCRP/ABCC2 presented as high immunoreactive scores (IRSs) was detected in the Refractory and Relapsed groups (p < 0.05 vs. Remission), respectively, whereas the IRS of P-gp/ABCB1 was low. Significant correlations were found among either MRP1/ABCC1 and survivin or BCRP/ABCC2 in the Refractory and Relapsed groups, respectively. In multiple linear regression analysis, ECOG status along with MRP1/ABCC1 or survivin and BRCP/ABCG2 was significantly associated with the prediction of the R-CHOP treatment response. CONCLUSIONS: DLBCL might harbor certain molecular signatures such as MRP1/ABCC1, survivin, and BCRP/ABCC2 overexpression that can predict resistance to R-CHOP.

Center for Biomedical Research Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Clinic of Hematology University Clinical Center of Serbia 2 Pasterova 11000 Belgrade Serbia

Department for Experimental Toxicology and Pharmacology National Poison Control Centre Military Medical Academy Crnotravska 17 11000 Belgrade Serbia

Department of Analytical Chemistry Faculty of Chemistry University of Belgrade Studenski trg 16 11000 Belgrade Serbia

Department of Chemistry Faculty of Science University of Hradec Kralove Rokitanskeho 62 50003 Hradec Kralove Czech Republic

Department of Gynecology and Obstetrics Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Hematology Clinic of Internal Medicine University Clinical Center Republic of Srpska 12 Beba 78000 Banja Luka Bosnia and Herzegovina

Department of Hematology Faculty of Medicine University of Belgrade 11000 Belgrade Serbia

Department of Internal Medicine Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Pathology Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Pharmacology Toxicology and Clinical Pharmacology Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Department of Surgery Faculty of Medicine University of Banja Luka Save Mrkalja 14 78000 Banja Luka Bosnia and Herzegovina

Institute for Medical Research National Institute of the Republic of Serbia Department for Cardiovascular Research University of Belgrade Dr Subotića 4 11000 Belgrade Serbia

Medical Faculty of the Military Medical Academy University of Defence Crnotravska 17 11000 Belgrade Serbia

Special Police Unit Ministry of Interior Trebevićka 12 A 11030 Belgrade Serbia

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015460
003      
CZ-PrNML
005      
20231020093447.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers15164106 $2 doi
035    __
$a (PubMed)37627134
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mandić, Danijela $u Department of Hematology, Clinic of Internal Medicine, University Clinical Center Republic of Srpska, 12 Beba, 78000 Banja Luka, Bosnia and Herzegovina $u Department of Internal Medicine, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina
245    10
$a Overexpression of MRP1/ABCC1, Survivin and BCRP/ABCC2 Predicts the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Treatment / $c D. Mandić, L. Nežić, L. Amdžić, N. Vojinović, R. Gajanin, M. Popović, J. Đeri, MT. Balint, J. Dumanović, Z. Milovanović, J. Grujić-Milanović, R. Škrbić, V. Jaćević
520    9_
$a BACKGROUND: Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience treatment resistance to the first-line R-CHOP regimen. ATP binding cassette (ABC) transporters and survivin might play a role in multidrug resistance (MDR) in various tumors. The aim was to investigate if the coexpression of ABC transporters and survivin was associated with R-CHOP treatment response. METHODS: The expression of Bcl-2, survivin, P-glycoprotein/ABCB1, MRP1/ABCC1, and BCRP/ABCC2 was analyzed using immunohistochemistry in tumor specimens obtained from patients with DLBCL, and classified according to the treatment response as Remission, Relapsed, and (primary) Refractory groups. All patients received R-CHOP or equivalent treatment. RESULTS: Bcl-2 was in strong positive correlation with clinical parameters and all biomarkers except P-gp/ABCB1. The overexpression of MRP1/ABCC1, survivin, and BCRP/ABCC2 presented as high immunoreactive scores (IRSs) was detected in the Refractory and Relapsed groups (p < 0.05 vs. Remission), respectively, whereas the IRS of P-gp/ABCB1 was low. Significant correlations were found among either MRP1/ABCC1 and survivin or BCRP/ABCC2 in the Refractory and Relapsed groups, respectively. In multiple linear regression analysis, ECOG status along with MRP1/ABCC1 or survivin and BRCP/ABCG2 was significantly associated with the prediction of the R-CHOP treatment response. CONCLUSIONS: DLBCL might harbor certain molecular signatures such as MRP1/ABCC1, survivin, and BCRP/ABCC2 overexpression that can predict resistance to R-CHOP.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nežić, Lana $u Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina $1 https://orcid.org/0000000242175437
700    1_
$a Amdžić, Ljiljana $u Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina
700    1_
$a Vojinović, Nataša $u Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina
700    1_
$a Gajanin, Radoslav $u Department of Pathology, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina
700    1_
$a Popović, Miroslav $u Department of Gynecology and Obstetrics, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina
700    1_
$a Đeri, Jugoslav $u Department of Surgery, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina
700    1_
$a Balint, Milena Todorović $u Department of Hematology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia $u Clinic of Hematology, University Clinical Center of Serbia, 2 Pasterova, 11000 Belgrade, Serbia $1 https://orcid.org/0000000209588811
700    1_
$a Dumanović, Jelena $u Department of Analytical Chemistry, Faculty of Chemistry, University of Belgrade, Studenski trg 16, 11000 Belgrade, Serbia $u Medical Faculty of the Military Medical Academy, University of Defence, Crnotravska 17, 11000 Belgrade, Serbia $1 https://orcid.org/0000000280789878
700    1_
$a Milovanović, Zoran $u Special Police Unit, Ministry of Interior, Trebevićka 12/A, 11030 Belgrade, Serbia
700    1_
$a Grujić-Milanović, Jelica $u Institute for Medical Research, National Institute of the Republic of Serbia, Department for Cardiovascular Research, University of Belgrade, Dr. Subotića 4, 11000 Belgrade, Serbia $1 https://orcid.org/0000000180143121
700    1_
$a Škrbić, Ranko $u Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina $u Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina $1 https://orcid.org/0000000266431781
700    1_
$a Jaćević, Vesna $u Medical Faculty of the Military Medical Academy, University of Defence, Crnotravska 17, 11000 Belgrade, Serbia $u Department for Experimental Toxicology and Pharmacology, National Poison Control Centre, Military Medical Academy, Crnotravska 17, 11000 Belgrade, Serbia $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 50003 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000151372638
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 15, č. 16 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37627134 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093440 $b ABA008
999    __
$a ok $b bmc $g 1997145 $s 1201822
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 16 $e 20230815 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20231010

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...